Introduction

According to recently compiled data by WHO, worldwide approximately 150 million people have diabetes mellitus, and this number is expected to be doubled by the year 2025

Traditional Significance

Natural products have long been used in traditional systems of medicine for diabetes. A number of them have gained universal appeal due to their safety and efficacy profile that have been evaluated using modern scientific techniques.

How it Works?

Inhibition of sodium–glucose co-transporter is a novel therapeutic approach to control diabetes, which is considered as a prominent change with respect to diabetes treatment options.

Why
Sabinsa ?

Sabinsa’s mission is to provide alternative and complementary natural products for human nutrition and well-being.
Presently Sabinsa owns over 217 USA & International patents, and has 100 pending patent applications worldwide. The company is also a three-time recipient of the prestigious Thomas Alva Edison Patent Award.
Emphasis on developing and bringing to market products with scientific and clinical substantiation is Sabinsa’s core business philosophy 
Committed and dedicated to the principles of innovation, tradition and research, Sabinsa supplies high quality innovative standardized herbal extracts, phytonutrients, probiotics, enzymes, spice extracts, minerals, specialty chemicals, and fine chemicals for applications in dietary supplements

PteroSol® Benefits

Traditional Uses

Because of its usefulness in managing diabetes, Pterocarpus marsupium is famously termed as “the miracle cure for diabetes” in Ayurveda literature. It is believed that vijaysar was first introduced by Susruta, the ancient surgeon from India for diabetes.

Since ancient times, Ayurvedic practitioners used blocks or pieces of Pterocarpus to control diabetes. Pterostilbene was identified as the major phenolic compound in Drakshasava, a traditional Ayurvedic medicinal preparation, used to treat cardiovascular and related problems (Paul et al., 1999), as well as in wood of Pterocarpus marsupium used by in the treatment of diabetes (Manickam et al., 1997).

Preclinical Evidence

In a study by Central Drug Research Institute, Lucknow, India, different extracts of heart wood of P. marsupium were tested for antidiabetic efficacy in streptozotocin (STZ)-induced diabetic rats.

Treatment showed a marked improvement on oral glucose tolerance post sucrose load as well as reduction in elevated blood glucose levels in diabetic rats. Furthermore, 10-day treatment with the ethanolic extract (100 mg/kg) resulted in decreased blood glucose, improved OGTT and increased serum insulin levels in STZ-treated rats.

Clinical Evidence

A multicenter, flexible dose, 12-week, open trial involving newly-diagnosed type 2 (NIDDM) patients was carried to assess efficacy of Pterocarpus extract. Patients were treated with increasing doses of Pterocarpus extract (i.e. 2 g, 3 g and 4 g at a gap of 4 weeks each). At the end of 12 weeks, 69% patients showed significant control of blood glucose (both fasting and postprandial levels).

Additionally, mean HbA1c was found to be decreased significantly (P < 0.001) at the end of the trial. There were no side-effects reported during the study period. In conclusion, Pterocarpus extract may be helpful in the treatment of newly-diagnosed or untreated mild NIDDM patients (ICMR, 1998).

Newsroom